The Alzheimer's Disease Amyloid Precursor Protein and its Neuritogenic Actions.


Journal

Current Alzheimer research
ISSN: 1875-5828
Titre abrégé: Curr Alzheimer Res
Pays: United Arab Emirates
ID NLM: 101208441

Informations de publication

Date de publication:
2021
Historique:
received: 01 06 2020
revised: 09 05 2021
accepted: 14 06 2021
pubmed: 10 12 2021
medline: 2 4 2022
entrez: 9 12 2021
Statut: ppublish

Résumé

The Amyloid Precursor Protein (APP) is principally known and studied for its involvement in Alzheimer's disease as the source of the amyloid β peptide; however, its physiological actions within the nervous system are also important as it is involved in a range of neuronal activities, including neurogenesis, synaptic plasticity, neurite outgrowth, and neuroprotection. Of the different neuronal functions that APP can affect, some may be relevant to APP's role in Alzheimer's disease, while others can be primarily related to its physiological roles. This review will focus on APP's neuritogenic actions and surmise the key molecular mechanisms, as well as the structural and signaling requirements, which form the basis for APP's neuritogenic effects. Deciphering the normal function(s) of APP is valuable to properly understanding its role in health as well as Alzheimer's disease.

Identifiants

pubmed: 34879801
pii: CAR-EPUB-119297
doi: 10.2174/1567205018666211208141017
doi:

Substances chimiques

Amyloid beta-Peptides 0
Amyloid beta-Protein Precursor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

772-786

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Luan Luu (L)

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences Macquarie University, Macquarie, NSW 2109,Australia.

Giuseppe D Ciccotosto (GD)

Department of Pharmacology and Therapeutics, The University of Melbourne, VIC 3010,Australia.

Roberto Cappai (R)

Department of Pharmacology and Therapeutics, The University of Melbourne, VIC 3010,Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH